Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

The dual role of viscosity in capillary rise.

Delannoy J, Lafon S, Koga Y, Reyssat É, Quéré D.

Soft Matter. 2019 Apr 7;15(13):2757-2761. doi: 10.1039/c8sm02485e. Epub 2019 Jan 29.

PMID:
30693361
2.

Quantitative study of the mineralogical composition of mineral dust aerosols by X-ray diffraction.

Nowak S, Lafon S, Caquineau S, Journet E, Laurent B.

Talanta. 2018 Aug 15;186:133-139. doi: 10.1016/j.talanta.2018.03.059. Epub 2018 Mar 22.

PMID:
29784340
3.

Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina.

Niborski LL, Grippo V, Lafón SO, Levitus G, García-Bournissen F, Ramirez JC, Burgos JM, Bisio M, Juiz NA, Ayala V, Coppede M, Herrera V, López C, Contreras A, Gómez KA, Elean JC, Mujica HD, Schijman AG, Levin MJ, Longhi SA.

Mem Inst Oswaldo Cruz. 2016 May 24;111(6):365-71. doi: 10.1590/0074-02760160006.

4.

Hierarchical reorganization of dimensions in OLAP visualizations.

Lafon S, Bouali F, Guinot C, Venturini G.

IEEE Trans Vis Comput Graph. 2013 Nov;19(11):1833-45. doi: 10.1109/TVCG.2013.93.

PMID:
24029904
5.

An investigation of bloodborne pathogen transmission due to multipatient sharing of insulin pens.

Hakre S, Upshaw-Combs DR, Sanders-Buell EE, Scoville SL, Kuper JD, Jagodzinski LL, Bradfield AN, Davison DC, Callis WG, Owens AB, Michael NL, O'Connell RJ, Peel SA, Gardner JW, Thompson ND, Hu DJ, Kim JH, Tovanabutra S, Scott PT, LaFon SG; Insulin Pen Investigation Team.

Mil Med. 2012 Aug;177(8):930-8.

PMID:
22934373
6.

Evaluation of in-house ELISA using Trypanosoma cruzi lysate and recombinant antigens for diagnosis of Chagas disease and discrimination of its clinical forms.

Longhi SA, Brandariz SB, Lafon SO, Niborski LL, Luquetti AO, Schijman AG, Levin MJ, Gómez KA.

Am J Trop Med Hyg. 2012 Aug;87(2):267-71. doi: 10.4269/ajtmh.2012.11-0533.

7.

Epidemiological survey of H1N1 influenza virus in cats in France.

Pingret JL, Rivière D, Lafon S, Etiévant M, Boucraut-Baralon C.

Vet Rec. 2010 Mar 6;166(10):307. doi: 10.1136/vr.c1262. No abstract available.

PMID:
20208085
8.

Data fusion and multicue data matching by diffusion maps.

Lafon S, Keller Y, Coifman RR.

IEEE Trans Pattern Anal Mach Intell. 2006 Nov;28(11):1784-97.

PMID:
17063683
9.
10.

Geometric diffusions as a tool for harmonic analysis and structure definition of data: diffusion maps.

Coifman RR, Lafon S, Lee AB, Maggioni M, Nadler B, Warner F, Zucker SW.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7426-31. Epub 2005 May 17.

11.

Geometric diffusions as a tool for harmonic analysis and structure definition of data: multiscale methods.

Coifman RR, Lafon S, Lee AB, Maggioni M, Nadler B, Warner F, Zucker SW.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7432-7. Epub 2005 May 17.

12.

Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.

Lanier ER, Ait-Khaled M, Scott J, Stone C, Melby T, Sturge G, St Clair M, Steel H, Hetherington S, Pearce G, Spreen W, Lafon S.

Antivir Ther. 2004 Feb;9(1):37-45.

PMID:
15040535
13.

Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.

Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S; CNA3003 International Study Team.

Antivir Ther. 2002 Mar;7(1):43-51.

PMID:
12008787
14.

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H.

Clin Ther. 2001 Oct;23(10):1603-14.

PMID:
11726000
15.

Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.

Drusano GL, D'Argenio DZ, Preston SL, Barone C, Symonds W, LaFon S, Rogers M, Prince W, Bye A, Bilello JA.

Antimicrob Agents Chemother. 2000 Jun;44(6):1655-9.

16.

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.

Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H.

Clin Infect Dis. 2000 Feb;30(2):313-8.

PMID:
10671334
17.

Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study.

Falloon J, Sargent S, Piscitelli SC, Bechtel C, LaFon SW, Sadler B, Walker RE, Kovacs JA, Polis MA, Davey RT Jr, Lane HC, Masur H.

Pharmacotherapy. 1999 Sep;19(9):1050-6.

PMID:
10610011
18.

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.

Kumar PN, Sweet DE, McDowell JA, Symonds W, Lou Y, Hetherington S, LaFon S.

Antimicrob Agents Chemother. 1999 Mar;43(3):603-8.

19.

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.

Saag MS, Sonnerborg A, Torres RA, Lancaster D, Gazzard BG, Schooley RT, Romero C, Kelleher D, Spreen W, LaFon S.

AIDS. 1998 Nov 12;12(16):F203-9.

PMID:
9833848
20.

Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.

Hughes WT, Sillos EM, LaFon S, Rogers M, Woolley JL, Davis C, Studenberg S, Pattishall E, Freeze T, Snyder G, Staton S.

J Infect Dis. 1998 Apr;177(4):1046-56.

PMID:
9534981
21.

A simple Trypanosoma cruzi enzyme-linked immunoassay for control of human infection in nonendemic areas.

Aznar C, Liegeard P, Mariette C, Lafon S, Levin MJ, Hontebeyrie M.

FEMS Immunol Med Microbiol. 1997 May;18(1):31-7.

22.

Leishmaniasis in Texas: epidemiology and clinical aspects of human cases.

McHugh CP, Melby PC, LaFon SG.

Am J Trop Med Hyg. 1996 Nov;55(5):547-55. Review.

PMID:
8940988
23.

Prevalence of anti-R-13 antibodies in human Trypanosoma cruzi infection.

Aznar C, Lopez-Bergami P, Brandariz S, Mariette C, Liegeard P, Alves MD, Barreiro EL, Carrasco R, Lafon S, Kaplan D, et al.

FEMS Immunol Med Microbiol. 1995 Dec;12(3-4):231-8.

PMID:
8745008
24.

Clinical experience with atovaquone on a treatment investigational new drug protocol for Pneumocystis carinii pneumonia.

White A, LaFon S, Rogers M, Andrews E, Brown N.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jul 1;9(3):280-5.

PMID:
7788426
25.
26.
27.

The 70-kDa heat-shock protein is a major antigenic determinant in human Trypanosoma cruzi/Leishmania braziliensis braziliensis mixed infection.

Levy Yeyati P, Bonnefoy S, Mirkin G, Debrabant A, Lafon S, Panebra A, Gonzalez-Cappa E, Dedet JP, Hontebeyrie-Joskowicz M, Levin MJ.

Immunol Lett. 1992 Jan;31(1):27-33.

PMID:
1548032
28.

A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome.

Falloon J, Kovacs J, Hughes W, O'Neill D, Polis M, Davey RT Jr, Rogers M, LaFon S, Feuerstein I, Lancaster D, et al.

N Engl J Med. 1991 Nov 28;325(22):1534-8.

29.

Recombinant Trypanosoma cruzi antigens and Chagas' disease diagnosis: analysis of a workshop.

Levin MJ, Franco da Silveira J, Frasch AC, Camargo ME, Lafon S, Degrave WM, Rangel-Aldao R.

FEMS Microbiol Immunol. 1991 Dec;4(1):11-9.

PMID:
1815706
30.

Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients.

Dohn MN, Frame PT, Baughman RP, Lafon SW, Smulian AG, Caldwell P, Rogers MD.

J Protozool. 1991 Nov-Dec;38(6):220S-221S.

PMID:
1818178
31.

Antiprotozoal activity of 3'-deoxyinosine. Inverse correlation to cleavage of the glycosidic bond.

Moorman AR, LaFon SW, Nelson DJ, Carter HH, Marr JJ, Berens RL.

Biochem Pharmacol. 1991 Jul 5;42(2):207-12.

PMID:
1859443
32.

Autoantibodies in Chagas' heart disease: possible markers of severe Chagas' heart complaint.

Levin MJ, Levitus G, Kerner N, Lafon S, Schijman A, Levy-Yeyati P, Finkieltein C, Chiale P, Schejtman D, Hontebeyrie-Joskowics M.

Mem Inst Oswaldo Cruz. 1990 Oct-Dec;85(4):539-43. No abstract available.

33.

Nucleotide cDNA and complete deduced amino acid sequence of a Trypanosoma cruzi ribosomal P protein (P-JL5).

Schijman AG, Dusetti NJ, Vazquez MP, Lafon S, Levy-Yeyati P, Levin MJ.

Nucleic Acids Res. 1990 Jun 11;18(11):3399. No abstract available.

34.

Prophylactically administered Retrovir in health care workers potentially exposed to the human immunodeficiency virus.

LaFon SW, Lehrman SN, Barry DW.

J Infect Dis. 1988 Aug;158(2):503. No abstract available.

PMID:
3042884
35.

Antigiardial activity of guanine arabinoside. Mechanism studies.

Miller RL, Nelson DJ, LaFon SW, Miller WH, Krenitsky TA.

Biochem Pharmacol. 1987 Aug 1;36(15):2519-25.

PMID:
2440445
36.

6-Thiopurine riboside analogs: their toxicity and metabolism in Leishmania donovani and mammalian cells.

LaFon SW, Cohn NK, Nelson DJ, Berens RL.

Adv Exp Med Biol. 1986;195 Pt B:565-71. No abstract available.

PMID:
3766244
37.

Inosine analogs. Their metabolism in mouse L cells and in Leishmania donovani.

LaFon SW, Nelson DJ, Berens RL, Marr JJ.

J Biol Chem. 1985 Aug 15;260(17):9660-5.

38.

Inosine analogs as chemotherapeutic agents for African trypanosomes: metabolism in trypanosomes and efficacy in tissue culture.

Fish WR, Marr JJ, Berens RL, Looker DL, Nelson DJ, LaFon SW, Balber AE.

Antimicrob Agents Chemother. 1985 Jan;27(1):33-6.

39.

Purine metabolism in the intact sporozoites and merozoites of Eimeria tenella.

LaFon SW, Nelson DJ.

Mol Biochem Parasitol. 1985 Jan;14(1):11-22.

PMID:
2580236
40.
41.

Monophosphates of formycin B and allopurinol riboside. Interactions with leishmanial and mammalian succino-AMP synthetase and GMP reductase.

Spector T, Jones TE, LaFon SW, Nelson DJ, Berens RL, Marr JJ.

Biochem Pharmacol. 1984 May 15;33(10):1611-7.

PMID:
6732835
42.

The metabolism of formycin B in Leishmania donovani.

Nelson DJ, Lafon SW, Jones TE, Spector T, Berens RL, Marr JJ.

Biochem Biophys Res Commun. 1982 Sep 16;108(1):349-54. No abstract available.

PMID:
7150292
43.

Antileishmanial action of 4-thiopyrazolo (3.4-d) pyrimidine and its ribonucleoside. Biological effects and metabolism.

Marr JJ, Berens RL, Nelson DJ, Krenitsky TA, Spector T, LaFon SW, Elion GB.

Biochem Pharmacol. 1982 Jan 15;31(2):143-8.

PMID:
7073876
44.

Purine and pyrimidine salvage pathways in Leishmania donovani.

LaFon SW, Nelson DJ, Berens RL, Marr JJ.

Biochem Pharmacol. 1982 Jan 15;31(2):231-8.

PMID:
7059364
45.

Purine metabolism in Trypanosoma cruzi.

Berens RL, Marr JJ, LaFon SW, Nelson DJ.

Mol Biochem Parasitol. 1981 Jul;3(3):187-96.

PMID:
6166862
46.

Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani.

Berens RL, Marr JJ, Nelson DJ, LaFon SW.

Biochem Pharmacol. 1980 Sep 1;29(17):2397-8. No abstract available.

PMID:
7426045
47.

Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation.

Nelson DJ, LaFon SW, Tuttle JV, Miller WH, Miller RL, Krenitsky TA, Elion GB, Berens RL, Marr JJ.

J Biol Chem. 1979 Nov 25;254(22):11544-9. No abstract available.

48.

Comparative metabolism of a new antileishmanial agent, allopurinol riboside, in the parasite and the host cell.

Nelson DJ, LaFon SW, Elion GB, Marr JJ, Berens RL.

Adv Exp Med Biol. 1979;122B:7-12.

PMID:
546162
49.

[Subacute rheumatism, terminal ileitis and renal amylosis].

Bernard R, Pinsard N, Unal D, Lafon S.

Arch Fr Pediatr. 1972 Apr;29(4):434-5. French. No abstract available.

PMID:
5053214
50.

[Anti-thymocyte globulins: clinical trials during kidney transplantation].

Murisasco A, Pollini J, Saingra S, Barnouin F, Lafon S, Mostefa-Kara S, Latour M.

Mars Med. 1972;109(9):541-8. French. No abstract available.

PMID:
4565307

Supplemental Content

Support Center